Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine reversal after thoracic anesthesia
2014-002021-35Phase 4Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jul 2014
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in neuromuscular block (NMB) comparing Sugammadex reversal with Neostigmine reversal (2 arms). Primary endpoint: Time from reversal administration to TOF-ratio = 0.9. Started Jul 2014; status: completed.
02
Drugs
Sugammadexneostigmine
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2014-002021-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002021-35.